nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—ERBB4—breast cancer	0.188	0.431	CbGaD
Lapatinib—ERBB2—breast cancer	0.139	0.318	CbGaD
Lapatinib—EGFR—breast cancer	0.0657	0.15	CbGaD
Lapatinib—EGFR—Docetaxel—breast cancer	0.0509	0.195	CbGbCtD
Lapatinib—CYP3A4—breast cancer	0.024	0.055	CbGaD
Lapatinib—ABCB1—breast cancer	0.02	0.0458	CbGaD
Lapatinib—ABCB1—Toremifene—breast cancer	0.0147	0.0566	CbGbCtD
Lapatinib—CYP3A4—Exemestane—breast cancer	0.0127	0.0489	CbGbCtD
Lapatinib—CYP2C8—Raloxifene—breast cancer	0.012	0.0462	CbGbCtD
Lapatinib—CYP3A4—Letrozole—breast cancer	0.0108	0.0416	CbGbCtD
Lapatinib—CYP3A4—Anastrozole—breast cancer	0.00966	0.0371	CbGbCtD
Lapatinib—CYP3A4—Toremifene—breast cancer	0.00883	0.0339	CbGbCtD
Lapatinib—CYP3A5—Tamoxifen—breast cancer	0.00827	0.0318	CbGbCtD
Lapatinib—CYP3A4—Fulvestrant—breast cancer	0.00821	0.0315	CbGbCtD
Lapatinib—CYP2C8—Tamoxifen—breast cancer	0.00795	0.0306	CbGbCtD
Lapatinib—CYP3A4—Thiotepa—breast cancer	0.00732	0.0281	CbGbCtD
Lapatinib—CYP3A4—Ixabepilone—breast cancer	0.00669	0.0257	CbGbCtD
Lapatinib—CYP2C19—Tamoxifen—breast cancer	0.00667	0.0256	CbGbCtD
Lapatinib—CYP3A5—Paclitaxel—breast cancer	0.00644	0.0247	CbGbCtD
Lapatinib—CYP3A5—Irinotecan—breast cancer	0.00635	0.0244	CbGbCtD
Lapatinib—CYP2C8—Paclitaxel—breast cancer	0.00619	0.0238	CbGbCtD
Lapatinib—ABCB1—Vinorelbine—breast cancer	0.00596	0.0229	CbGbCtD
Lapatinib—CYP2C8—Fluorouracil—breast cancer	0.00586	0.0225	CbGbCtD
Lapatinib—ABCB1—Tamoxifen—breast cancer	0.00538	0.0207	CbGbCtD
Lapatinib—ABCB1—Mitoxantrone—breast cancer	0.00525	0.0202	CbGbCtD
Lapatinib—CYP3A4—Raloxifene—breast cancer	0.00488	0.0188	CbGbCtD
Lapatinib—CYP3A5—Docetaxel—breast cancer	0.00466	0.0179	CbGbCtD
Lapatinib—ABCB1—Gemcitabine—breast cancer	0.00464	0.0178	CbGbCtD
Lapatinib—ABCB1—Paclitaxel—breast cancer	0.00419	0.0161	CbGbCtD
Lapatinib—ABCB1—Irinotecan—breast cancer	0.00413	0.0159	CbGbCtD
Lapatinib—ABCB1—Vinblastine—breast cancer	0.00368	0.0141	CbGbCtD
Lapatinib—CYP3A4—Vinorelbine—breast cancer	0.00357	0.0137	CbGbCtD
Lapatinib—CYP3A4—Tamoxifen—breast cancer	0.00323	0.0124	CbGbCtD
Lapatinib—CYP3A4—Mitoxantrone—breast cancer	0.00315	0.0121	CbGbCtD
Lapatinib—ABCB1—Docetaxel—breast cancer	0.00303	0.0116	CbGbCtD
Lapatinib—CYP3A4—Paclitaxel—breast cancer	0.00251	0.00964	CbGbCtD
Lapatinib—CYP3A4—Irinotecan—breast cancer	0.00248	0.00951	CbGbCtD
Lapatinib—ABCB1—Doxorubicin—breast cancer	0.00226	0.00868	CbGbCtD
Lapatinib—CYP3A4—Vinblastine—breast cancer	0.0022	0.00846	CbGbCtD
Lapatinib—ABCB1—Methotrexate—breast cancer	0.00219	0.0084	CbGbCtD
Lapatinib—PIK3C2B—mammary gland—breast cancer	0.00216	0.0406	CbGeAlD
Lapatinib—TAP1—nipple—breast cancer	0.0019	0.0358	CbGeAlD
Lapatinib—CYP3A4—Docetaxel—breast cancer	0.00182	0.00697	CbGbCtD
Lapatinib—PIK3C2B—nipple—breast cancer	0.00178	0.0336	CbGeAlD
Lapatinib—ERBB2—mammary gland—breast cancer	0.00168	0.0316	CbGeAlD
Lapatinib—ERBB4—mammary gland—breast cancer	0.00168	0.0316	CbGeAlD
Lapatinib—EGFR—mammary gland—breast cancer	0.00142	0.0268	CbGeAlD
Lapatinib—ERBB2—nipple—breast cancer	0.00139	0.0261	CbGeAlD
Lapatinib—CYP3A4—Doxorubicin—breast cancer	0.00135	0.0052	CbGbCtD
Lapatinib—PI4KB—nipple—breast cancer	0.0013	0.0245	CbGeAlD
Lapatinib—TAP1—endometrium—breast cancer	0.00115	0.0216	CbGeAlD
Lapatinib—ERBB4—embryo—breast cancer	0.00114	0.0216	CbGeAlD
Lapatinib—ERBB2—embryo—breast cancer	0.00114	0.0216	CbGeAlD
Lapatinib—PIK3C2B—endometrium—breast cancer	0.00108	0.0203	CbGeAlD
Lapatinib—TAP1—pituitary gland—breast cancer	0.00104	0.0196	CbGeAlD
Lapatinib—TAP1—adipose tissue—breast cancer	0.00103	0.0195	CbGeAlD
Lapatinib—PIK3C2B—pituitary gland—breast cancer	0.000974	0.0184	CbGeAlD
Lapatinib—PIK3C2B—adipose tissue—breast cancer	0.000971	0.0183	CbGeAlD
Lapatinib—ERBB2—epithelium—breast cancer	0.000934	0.0176	CbGeAlD
Lapatinib—ERBB4—epithelium—breast cancer	0.000934	0.0176	CbGeAlD
Lapatinib—TAP1—adrenal gland—breast cancer	0.000927	0.0175	CbGeAlD
Lapatinib—TAP1—bone marrow—breast cancer	0.000897	0.0169	CbGeAlD
Lapatinib—PIK3C2B—female reproductive system—breast cancer	0.000892	0.0168	CbGeAlD
Lapatinib—ERBB2—skin of body—breast cancer	0.000888	0.0167	CbGeAlD
Lapatinib—PIK3C2B—adrenal gland—breast cancer	0.000871	0.0164	CbGeAlD
Lapatinib—TAP1—female gonad—breast cancer	0.000865	0.0163	CbGeAlD
Lapatinib—PIK3C2B—bone marrow—breast cancer	0.000842	0.0159	CbGeAlD
Lapatinib—ERBB2—endometrium—breast cancer	0.000837	0.0158	CbGeAlD
Lapatinib—Gefitinib—CHEK2—breast cancer	0.00082	0.296	CrCbGaD
Lapatinib—PIK3C2B—female gonad—breast cancer	0.000812	0.0153	CbGeAlD
Lapatinib—PI4KB—endometrium—breast cancer	0.000784	0.0148	CbGeAlD
Lapatinib—ERBB2—uterus—breast cancer	0.000772	0.0145	CbGeAlD
Lapatinib—ERBB4—pituitary gland—breast cancer	0.000758	0.0143	CbGeAlD
Lapatinib—PIK3C2B—endocrine gland—breast cancer	0.000755	0.0142	CbGeAlD
Lapatinib—ERBB2—adipose tissue—breast cancer	0.000755	0.0142	CbGeAlD
Lapatinib—ERBB4—adipose tissue—breast cancer	0.000755	0.0142	CbGeAlD
Lapatinib—Gefitinib—ERBB3—breast cancer	0.000731	0.264	CrCbGaD
Lapatinib—PI4KB—uterus—breast cancer	0.000723	0.0136	CbGeAlD
Lapatinib—PI4KB—pituitary gland—breast cancer	0.00071	0.0134	CbGeAlD
Lapatinib—PI4KB—adipose tissue—breast cancer	0.000707	0.0133	CbGeAlD
Lapatinib—ERBB2—female reproductive system—breast cancer	0.000694	0.0131	CbGeAlD
Lapatinib—ERBB4—female reproductive system—breast cancer	0.000694	0.0131	CbGeAlD
Lapatinib—ERBB2—adrenal gland—breast cancer	0.000677	0.0128	CbGeAlD
Lapatinib—EGFR—uterus—breast cancer	0.000654	0.0123	CbGeAlD
Lapatinib—PI4KB—female reproductive system—breast cancer	0.00065	0.0122	CbGeAlD
Lapatinib—EGFR—adipose tissue—breast cancer	0.00064	0.0121	CbGeAlD
Lapatinib—PI4KB—adrenal gland—breast cancer	0.000634	0.0119	CbGeAlD
Lapatinib—ERBB2—female gonad—breast cancer	0.000631	0.0119	CbGeAlD
Lapatinib—PI4KB—bone marrow—breast cancer	0.000613	0.0116	CbGeAlD
Lapatinib—PI4KB—female gonad—breast cancer	0.000591	0.0111	CbGeAlD
Lapatinib—ERBB2—endocrine gland—breast cancer	0.000587	0.0111	CbGeAlD
Lapatinib—ERBB4—endocrine gland—breast cancer	0.000587	0.0111	CbGeAlD
Lapatinib—EGFR—adrenal gland—breast cancer	0.000574	0.0108	CbGeAlD
Lapatinib—TAP1—lymph node—breast cancer	0.000556	0.0105	CbGeAlD
Lapatinib—PI4KB—endocrine gland—breast cancer	0.00055	0.0104	CbGeAlD
Lapatinib—EGFR—female gonad—breast cancer	0.000535	0.0101	CbGeAlD
Lapatinib—PIK3C2B—lymph node—breast cancer	0.000522	0.00983	CbGeAlD
Lapatinib—CYP2C8—mammary gland—breast cancer	0.000456	0.00858	CbGeAlD
Lapatinib—ERBB2—lymph node—breast cancer	0.000406	0.00765	CbGeAlD
Lapatinib—PI4KB—lymph node—breast cancer	0.00038	0.00716	CbGeAlD
Lapatinib—PIK3C2B—Topotecan—Irinotecan—breast cancer	0.000372	0.129	CbGdCrCtD
Lapatinib—EGFR—lymph node—breast cancer	0.000344	0.00648	CbGeAlD
Lapatinib—PIK3C2B—Vindesine—Vinorelbine—breast cancer	0.000333	0.115	CbGdCrCtD
Lapatinib—Gefitinib—EGFR—breast cancer	0.000328	0.118	CrCbGaD
Lapatinib—ERBB2—Topotecan—Irinotecan—breast cancer	0.000306	0.106	CbGdCrCtD
Lapatinib—PIK3C2B—Vindesine—Vinblastine—breast cancer	0.000266	0.0922	CbGdCrCtD
Lapatinib—Gefitinib—ABCG2—breast cancer	0.000239	0.0865	CrCbGaD
Lapatinib—CYP2C8—endometrium—breast cancer	0.000228	0.00429	CbGeAlD
Lapatinib—CYP2C8—pituitary gland—breast cancer	0.000206	0.00388	CbGeAlD
Lapatinib—CYP2C8—female reproductive system—breast cancer	0.000189	0.00355	CbGeAlD
Lapatinib—Gefitinib—CYP1A1—breast cancer	0.000188	0.0677	CrCbGaD
Lapatinib—CYP3A5—adipose tissue—breast cancer	0.000185	0.00349	CbGeAlD
Lapatinib—CYP2C19—endocrine gland—breast cancer	0.000183	0.00344	CbGeAlD
Lapatinib—PIK3C2B—Vincristine—Vinorelbine—breast cancer	0.000179	0.0622	CbGdCrCtD
Lapatinib—PIK3C2B—Vinorelbine—Vinblastine—breast cancer	0.000168	0.0582	CbGdCrCtD
Lapatinib—CYP2C8—endocrine gland—breast cancer	0.00016	0.00301	CbGeAlD
Lapatinib—ERBB2—Doxorubicin—Idarubicin—breast cancer	0.000157	0.0544	CbGdCrCtD
Lapatinib—ERBB2—Epirubicin—Idarubicin—breast cancer	0.000157	0.0544	CbGdCrCtD
Lapatinib—CYP3A5—female gonad—breast cancer	0.000155	0.00292	CbGeAlD
Lapatinib—ABCB1—embryo—breast cancer	0.000149	0.00281	CbGeAlD
Lapatinib—PIK3C2B—Vinblastine—Vinorelbine—breast cancer	0.000144	0.0501	CbGdCrCtD
Lapatinib—CYP3A5—endocrine gland—breast cancer	0.000144	0.00271	CbGeAlD
Lapatinib—PIK3C2B—Vincristine—Vinblastine—breast cancer	0.000143	0.0498	CbGdCrCtD
Lapatinib—Gefitinib—CYP2D6—breast cancer	0.00014	0.0504	CrCbGaD
Lapatinib—CYP3A4—female reproductive system—breast cancer	0.000128	0.00241	CbGeAlD
Lapatinib—ABCB1—epithelium—breast cancer	0.000122	0.00229	CbGeAlD
Lapatinib—Gefitinib—CYP3A4—breast cancer	0.00012	0.0432	CrCbGaD
Lapatinib—ABCB1—endometrium—breast cancer	0.000109	0.00206	CbGeAlD
Lapatinib—CYP3A4—endocrine gland—breast cancer	0.000108	0.00204	CbGeAlD
Lapatinib—PIK3C2B—Testosterone Propionate—Fluoxymesterone—breast cancer	0.000105	0.0365	CbGdCrCtD
Lapatinib—Gefitinib—ALB—breast cancer	0.000104	0.0377	CrCbGaD
Lapatinib—ABCB1—uterus—breast cancer	0.000101	0.00189	CbGeAlD
Lapatinib—Gefitinib—ABCB1—breast cancer	9.97e-05	0.036	CrCbGaD
Lapatinib—ABCB1—pituitary gland—breast cancer	9.87e-05	0.00186	CbGeAlD
Lapatinib—ABCB1—adipose tissue—breast cancer	9.83e-05	0.00185	CbGeAlD
Lapatinib—ERBB2—Triamcinolone—Fluoxymesterone—breast cancer	9.29e-05	0.0322	CbGdCrCtD
Lapatinib—ABCB1—female reproductive system—breast cancer	9.04e-05	0.0017	CbGeAlD
Lapatinib—ERBB2—Desoximetasone—Fluoxymesterone—breast cancer	8.82e-05	0.0306	CbGdCrCtD
Lapatinib—ABCB1—adrenal gland—breast cancer	8.82e-05	0.00166	CbGeAlD
Lapatinib—PIK3C2B—Danazol—Fluoxymesterone—breast cancer	8.74e-05	0.0303	CbGdCrCtD
Lapatinib—ABCB1—bone marrow—breast cancer	8.53e-05	0.00161	CbGeAlD
Lapatinib—ABCB1—female gonad—breast cancer	8.22e-05	0.00155	CbGeAlD
Lapatinib—PIK3C2B—Norethindrone—Fluoxymesterone—breast cancer	7.87e-05	0.0273	CbGdCrCtD
Lapatinib—ABCB1—endocrine gland—breast cancer	7.65e-05	0.00144	CbGeAlD
Lapatinib—ERBB2—Doxorubicin—Epirubicin—breast cancer	7.2e-05	0.025	CbGdCrCtD
Lapatinib—PIK3C2B—Azacitidine—Gemcitabine—breast cancer	6.76e-05	0.0234	CbGdCrCtD
Lapatinib—ERBB2—Epirubicin—Doxorubicin—breast cancer	6.66e-05	0.0231	CbGdCrCtD
Lapatinib—ABCB1—lymph node—breast cancer	5.29e-05	0.000996	CbGeAlD
Lapatinib—Anaemia—Capecitabine—breast cancer	4.32e-05	0.000357	CcSEcCtD
Lapatinib—Palpitations—Docetaxel—breast cancer	4.27e-05	0.000353	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Paclitaxel—breast cancer	4.24e-05	0.00035	CcSEcCtD
Lapatinib—Cough—Docetaxel—breast cancer	4.22e-05	0.000348	CcSEcCtD
Lapatinib—Hepatobiliary disease—Methotrexate—breast cancer	4.21e-05	0.000348	CcSEcCtD
Lapatinib—Insomnia—Paclitaxel—breast cancer	4.21e-05	0.000348	CcSEcCtD
Lapatinib—Epistaxis—Methotrexate—breast cancer	4.2e-05	0.000347	CcSEcCtD
Lapatinib—Hypersensitivity—Mitoxantrone—breast cancer	4.2e-05	0.000347	CcSEcCtD
Lapatinib—Hypersensitivity—Irinotecan—breast cancer	4.2e-05	0.000347	CcSEcCtD
Lapatinib—Vomiting—Thiotepa—breast cancer	4.2e-05	0.000347	CcSEcCtD
Lapatinib—Pneumonia—Epirubicin—breast cancer	4.19e-05	0.000347	CcSEcCtD
Lapatinib—Leukopenia—Capecitabine—breast cancer	4.19e-05	0.000346	CcSEcCtD
Lapatinib—Infestation—Epirubicin—breast cancer	4.17e-05	0.000345	CcSEcCtD
Lapatinib—Infestation NOS—Epirubicin—breast cancer	4.17e-05	0.000345	CcSEcCtD
Lapatinib—Rash—Thiotepa—breast cancer	4.16e-05	0.000344	CcSEcCtD
Lapatinib—Dermatitis—Thiotepa—breast cancer	4.16e-05	0.000344	CcSEcCtD
Lapatinib—Dyspnoea—Paclitaxel—breast cancer	4.15e-05	0.000343	CcSEcCtD
Lapatinib—Headache—Thiotepa—breast cancer	4.14e-05	0.000342	CcSEcCtD
Lapatinib—Palpitations—Capecitabine—breast cancer	4.13e-05	0.000342	CcSEcCtD
Lapatinib—Arthralgia—Docetaxel—breast cancer	4.11e-05	0.00034	CcSEcCtD
Lapatinib—Myalgia—Docetaxel—breast cancer	4.11e-05	0.00034	CcSEcCtD
Lapatinib—Nausea—Vinorelbine—breast cancer	4.11e-05	0.000339	CcSEcCtD
Lapatinib—Dyspepsia—Paclitaxel—breast cancer	4.09e-05	0.000338	CcSEcCtD
Lapatinib—Asthenia—Mitoxantrone—breast cancer	4.09e-05	0.000338	CcSEcCtD
Lapatinib—Asthenia—Irinotecan—breast cancer	4.09e-05	0.000338	CcSEcCtD
Lapatinib—Neuropathy peripheral—Epirubicin—breast cancer	4.09e-05	0.000338	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	4.08e-05	0.000337	CcSEcCtD
Lapatinib—Cough—Capecitabine—breast cancer	4.08e-05	0.000337	CcSEcCtD
Lapatinib—Stomatitis—Epirubicin—breast cancer	4.06e-05	0.000336	CcSEcCtD
Lapatinib—Neutropenia—Doxorubicin—breast cancer	4.05e-05	0.000334	CcSEcCtD
Lapatinib—Decreased appetite—Paclitaxel—breast cancer	4.04e-05	0.000334	CcSEcCtD
Lapatinib—Hypersensitivity—Fluorouracil—breast cancer	4.02e-05	0.000333	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Paclitaxel—breast cancer	4.02e-05	0.000332	CcSEcCtD
Lapatinib—Fatigue—Paclitaxel—breast cancer	4.01e-05	0.000331	CcSEcCtD
Lapatinib—Asthenia—Gemcitabine—breast cancer	3.99e-05	0.000329	CcSEcCtD
Lapatinib—Arthralgia—Capecitabine—breast cancer	3.98e-05	0.000329	CcSEcCtD
Lapatinib—Myalgia—Capecitabine—breast cancer	3.98e-05	0.000329	CcSEcCtD
Lapatinib—Constipation—Paclitaxel—breast cancer	3.98e-05	0.000329	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	3.95e-05	0.000327	CcSEcCtD
Lapatinib—Hepatobiliary disease—Epirubicin—breast cancer	3.94e-05	0.000326	CcSEcCtD
Lapatinib—Anaphylactic shock—Docetaxel—breast cancer	3.94e-05	0.000326	CcSEcCtD
Lapatinib—Epistaxis—Epirubicin—breast cancer	3.93e-05	0.000325	CcSEcCtD
Lapatinib—Pruritus—Gemcitabine—breast cancer	3.93e-05	0.000325	CcSEcCtD
Lapatinib—Nausea—Thiotepa—breast cancer	3.92e-05	0.000324	CcSEcCtD
Lapatinib—Infection—Docetaxel—breast cancer	3.92e-05	0.000324	CcSEcCtD
Lapatinib—Diarrhoea—Mitoxantrone—breast cancer	3.9e-05	0.000322	CcSEcCtD
Lapatinib—Diarrhoea—Irinotecan—breast cancer	3.9e-05	0.000322	CcSEcCtD
Lapatinib—Pneumonia—Doxorubicin—breast cancer	3.88e-05	0.000321	CcSEcCtD
Lapatinib—Nervous system disorder—Docetaxel—breast cancer	3.87e-05	0.000319	CcSEcCtD
Lapatinib—Pruritus—Fluorouracil—breast cancer	3.86e-05	0.000319	CcSEcCtD
Lapatinib—Infestation—Doxorubicin—breast cancer	3.86e-05	0.000319	CcSEcCtD
Lapatinib—Infestation NOS—Doxorubicin—breast cancer	3.86e-05	0.000319	CcSEcCtD
Lapatinib—Skin disorder—Docetaxel—breast cancer	3.83e-05	0.000316	CcSEcCtD
Lapatinib—Gastrointestinal pain—Paclitaxel—breast cancer	3.8e-05	0.000314	CcSEcCtD
Lapatinib—Diarrhoea—Gemcitabine—breast cancer	3.8e-05	0.000314	CcSEcCtD
Lapatinib—Infection—Capecitabine—breast cancer	3.79e-05	0.000313	CcSEcCtD
Lapatinib—Neuropathy peripheral—Doxorubicin—breast cancer	3.78e-05	0.000312	CcSEcCtD
Lapatinib—Stomatitis—Doxorubicin—breast cancer	3.76e-05	0.000311	CcSEcCtD
Lapatinib—Anorexia—Docetaxel—breast cancer	3.76e-05	0.000311	CcSEcCtD
Lapatinib—Nervous system disorder—Capecitabine—breast cancer	3.74e-05	0.000309	CcSEcCtD
Lapatinib—Diarrhoea—Fluorouracil—breast cancer	3.74e-05	0.000309	CcSEcCtD
Lapatinib—Cardiac disorder—Methotrexate—breast cancer	3.71e-05	0.000307	CcSEcCtD
Lapatinib—Skin disorder—Capecitabine—breast cancer	3.71e-05	0.000306	CcSEcCtD
Lapatinib—Connective tissue disorder—Epirubicin—breast cancer	3.68e-05	0.000304	CcSEcCtD
Lapatinib—Abdominal pain—Paclitaxel—breast cancer	3.68e-05	0.000304	CcSEcCtD
Lapatinib—Hepatobiliary disease—Doxorubicin—breast cancer	3.65e-05	0.000301	CcSEcCtD
Lapatinib—Epistaxis—Doxorubicin—breast cancer	3.64e-05	0.000301	CcSEcCtD
Lapatinib—Anorexia—Capecitabine—breast cancer	3.64e-05	0.000301	CcSEcCtD
Lapatinib—Angiopathy—Methotrexate—breast cancer	3.63e-05	0.0003	CcSEcCtD
Lapatinib—Vomiting—Mitoxantrone—breast cancer	3.63e-05	0.0003	CcSEcCtD
Lapatinib—Vomiting—Irinotecan—breast cancer	3.63e-05	0.0003	CcSEcCtD
Lapatinib—Immune system disorder—Methotrexate—breast cancer	3.61e-05	0.000299	CcSEcCtD
Lapatinib—Mediastinal disorder—Methotrexate—breast cancer	3.6e-05	0.000298	CcSEcCtD
Lapatinib—Rash—Mitoxantrone—breast cancer	3.6e-05	0.000297	CcSEcCtD
Lapatinib—Rash—Irinotecan—breast cancer	3.6e-05	0.000297	CcSEcCtD
Lapatinib—Dermatitis—Mitoxantrone—breast cancer	3.59e-05	0.000297	CcSEcCtD
Lapatinib—Dermatitis—Irinotecan—breast cancer	3.59e-05	0.000297	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Docetaxel—breast cancer	3.59e-05	0.000297	CcSEcCtD
Lapatinib—Headache—Mitoxantrone—breast cancer	3.57e-05	0.000295	CcSEcCtD
Lapatinib—Headache—Irinotecan—breast cancer	3.57e-05	0.000295	CcSEcCtD
Lapatinib—Insomnia—Docetaxel—breast cancer	3.57e-05	0.000295	CcSEcCtD
Lapatinib—Alopecia—Methotrexate—breast cancer	3.53e-05	0.000292	CcSEcCtD
Lapatinib—Vomiting—Gemcitabine—breast cancer	3.53e-05	0.000292	CcSEcCtD
Lapatinib—Dyspnoea—Docetaxel—breast cancer	3.51e-05	0.00029	CcSEcCtD
Lapatinib—Mental disorder—Methotrexate—breast cancer	3.5e-05	0.00029	CcSEcCtD
Lapatinib—Rash—Gemcitabine—breast cancer	3.5e-05	0.000289	CcSEcCtD
Lapatinib—Dermatitis—Gemcitabine—breast cancer	3.5e-05	0.000289	CcSEcCtD
Lapatinib—Malnutrition—Methotrexate—breast cancer	3.48e-05	0.000288	CcSEcCtD
Lapatinib—Headache—Gemcitabine—breast cancer	3.48e-05	0.000288	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Capecitabine—breast cancer	3.48e-05	0.000287	CcSEcCtD
Lapatinib—Cardiac disorder—Epirubicin—breast cancer	3.47e-05	0.000287	CcSEcCtD
Lapatinib—Vomiting—Fluorouracil—breast cancer	3.47e-05	0.000287	CcSEcCtD
Lapatinib—Dyspepsia—Docetaxel—breast cancer	3.47e-05	0.000287	CcSEcCtD
Lapatinib—Insomnia—Capecitabine—breast cancer	3.45e-05	0.000285	CcSEcCtD
Lapatinib—Rash—Fluorouracil—breast cancer	3.44e-05	0.000285	CcSEcCtD
Lapatinib—Dermatitis—Fluorouracil—breast cancer	3.44e-05	0.000284	CcSEcCtD
Lapatinib—Decreased appetite—Docetaxel—breast cancer	3.43e-05	0.000283	CcSEcCtD
Lapatinib—Hypersensitivity—Paclitaxel—breast cancer	3.43e-05	0.000283	CcSEcCtD
Lapatinib—Headache—Fluorouracil—breast cancer	3.42e-05	0.000283	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Docetaxel—breast cancer	3.4e-05	0.000281	CcSEcCtD
Lapatinib—Connective tissue disorder—Doxorubicin—breast cancer	3.4e-05	0.000281	CcSEcCtD
Lapatinib—Dyspnoea—Capecitabine—breast cancer	3.4e-05	0.000281	CcSEcCtD
Lapatinib—Fatigue—Docetaxel—breast cancer	3.4e-05	0.000281	CcSEcCtD
Lapatinib—Angiopathy—Epirubicin—breast cancer	3.4e-05	0.000281	CcSEcCtD
Lapatinib—Nausea—Irinotecan—breast cancer	3.39e-05	0.00028	CcSEcCtD
Lapatinib—Nausea—Mitoxantrone—breast cancer	3.39e-05	0.00028	CcSEcCtD
Lapatinib—Immune system disorder—Epirubicin—breast cancer	3.38e-05	0.000279	CcSEcCtD
Lapatinib—Mediastinal disorder—Epirubicin—breast cancer	3.37e-05	0.000279	CcSEcCtD
Lapatinib—Constipation—Docetaxel—breast cancer	3.37e-05	0.000279	CcSEcCtD
Lapatinib—Back pain—Methotrexate—breast cancer	3.37e-05	0.000278	CcSEcCtD
Lapatinib—Dyspepsia—Capecitabine—breast cancer	3.36e-05	0.000278	CcSEcCtD
Lapatinib—Asthenia—Paclitaxel—breast cancer	3.34e-05	0.000276	CcSEcCtD
Lapatinib—Decreased appetite—Capecitabine—breast cancer	3.32e-05	0.000274	CcSEcCtD
Lapatinib—Alopecia—Epirubicin—breast cancer	3.31e-05	0.000273	CcSEcCtD
Lapatinib—Nausea—Gemcitabine—breast cancer	3.3e-05	0.000273	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Capecitabine—breast cancer	3.3e-05	0.000272	CcSEcCtD
Lapatinib—Fatigue—Capecitabine—breast cancer	3.29e-05	0.000272	CcSEcCtD
Lapatinib—Pruritus—Paclitaxel—breast cancer	3.29e-05	0.000272	CcSEcCtD
Lapatinib—Mental disorder—Epirubicin—breast cancer	3.28e-05	0.000271	CcSEcCtD
Lapatinib—Constipation—Capecitabine—breast cancer	3.26e-05	0.00027	CcSEcCtD
Lapatinib—Malnutrition—Epirubicin—breast cancer	3.26e-05	0.000269	CcSEcCtD
Lapatinib—Nausea—Fluorouracil—breast cancer	3.24e-05	0.000268	CcSEcCtD
Lapatinib—Gastrointestinal pain—Docetaxel—breast cancer	3.22e-05	0.000266	CcSEcCtD
Lapatinib—Anaemia—Methotrexate—breast cancer	3.22e-05	0.000266	CcSEcCtD
Lapatinib—Cardiac disorder—Doxorubicin—breast cancer	3.21e-05	0.000266	CcSEcCtD
Lapatinib—Diarrhoea—Paclitaxel—breast cancer	3.18e-05	0.000263	CcSEcCtD
Lapatinib—Back pain—Epirubicin—breast cancer	3.15e-05	0.00026	CcSEcCtD
Lapatinib—Angiopathy—Doxorubicin—breast cancer	3.14e-05	0.00026	CcSEcCtD
Lapatinib—Immune system disorder—Doxorubicin—breast cancer	3.13e-05	0.000258	CcSEcCtD
Lapatinib—Gastrointestinal pain—Capecitabine—breast cancer	3.12e-05	0.000258	CcSEcCtD
Lapatinib—Mediastinal disorder—Doxorubicin—breast cancer	3.12e-05	0.000258	CcSEcCtD
Lapatinib—Abdominal pain—Docetaxel—breast cancer	3.12e-05	0.000258	CcSEcCtD
Lapatinib—Leukopenia—Methotrexate—breast cancer	3.12e-05	0.000258	CcSEcCtD
Lapatinib—Alopecia—Doxorubicin—breast cancer	3.06e-05	0.000253	CcSEcCtD
Lapatinib—Cough—Methotrexate—breast cancer	3.04e-05	0.000251	CcSEcCtD
Lapatinib—Mental disorder—Doxorubicin—breast cancer	3.03e-05	0.000251	CcSEcCtD
Lapatinib—Abdominal pain—Capecitabine—breast cancer	3.02e-05	0.000249	CcSEcCtD
Lapatinib—Malnutrition—Doxorubicin—breast cancer	3.01e-05	0.000249	CcSEcCtD
Lapatinib—Anaemia—Epirubicin—breast cancer	3.01e-05	0.000249	CcSEcCtD
Lapatinib—Myalgia—Methotrexate—breast cancer	2.96e-05	0.000245	CcSEcCtD
Lapatinib—Arthralgia—Methotrexate—breast cancer	2.96e-05	0.000245	CcSEcCtD
Lapatinib—Vomiting—Paclitaxel—breast cancer	2.96e-05	0.000244	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	2.94e-05	0.000243	CcSEcCtD
Lapatinib—Rash—Paclitaxel—breast cancer	2.93e-05	0.000242	CcSEcCtD
Lapatinib—Dermatitis—Paclitaxel—breast cancer	2.93e-05	0.000242	CcSEcCtD
Lapatinib—Leukopenia—Epirubicin—breast cancer	2.92e-05	0.000241	CcSEcCtD
Lapatinib—Back pain—Doxorubicin—breast cancer	2.92e-05	0.000241	CcSEcCtD
Lapatinib—Headache—Paclitaxel—breast cancer	2.91e-05	0.000241	CcSEcCtD
Lapatinib—Hypersensitivity—Docetaxel—breast cancer	2.9e-05	0.00024	CcSEcCtD
Lapatinib—Palpitations—Epirubicin—breast cancer	2.88e-05	0.000238	CcSEcCtD
Lapatinib—Cough—Epirubicin—breast cancer	2.84e-05	0.000235	CcSEcCtD
Lapatinib—Anaphylactic shock—Methotrexate—breast cancer	2.84e-05	0.000235	CcSEcCtD
Lapatinib—Asthenia—Docetaxel—breast cancer	2.83e-05	0.000234	CcSEcCtD
Lapatinib—Infection—Methotrexate—breast cancer	2.82e-05	0.000233	CcSEcCtD
Lapatinib—Hypersensitivity—Capecitabine—breast cancer	2.81e-05	0.000232	CcSEcCtD
Lapatinib—Pruritus—Docetaxel—breast cancer	2.79e-05	0.00023	CcSEcCtD
Lapatinib—Nervous system disorder—Methotrexate—breast cancer	2.79e-05	0.00023	CcSEcCtD
Lapatinib—Anaemia—Doxorubicin—breast cancer	2.79e-05	0.00023	CcSEcCtD
Lapatinib—Arthralgia—Epirubicin—breast cancer	2.77e-05	0.000229	CcSEcCtD
Lapatinib—Myalgia—Epirubicin—breast cancer	2.77e-05	0.000229	CcSEcCtD
Lapatinib—Nausea—Paclitaxel—breast cancer	2.76e-05	0.000228	CcSEcCtD
Lapatinib—Skin disorder—Methotrexate—breast cancer	2.76e-05	0.000228	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.75e-05	0.000228	CcSEcCtD
Lapatinib—Asthenia—Capecitabine—breast cancer	2.74e-05	0.000226	CcSEcCtD
Lapatinib—Anorexia—Methotrexate—breast cancer	2.71e-05	0.000224	CcSEcCtD
Lapatinib—Pruritus—Capecitabine—breast cancer	2.7e-05	0.000223	CcSEcCtD
Lapatinib—Leukopenia—Doxorubicin—breast cancer	2.7e-05	0.000223	CcSEcCtD
Lapatinib—Diarrhoea—Docetaxel—breast cancer	2.7e-05	0.000223	CcSEcCtD
Lapatinib—Palpitations—Doxorubicin—breast cancer	2.66e-05	0.00022	CcSEcCtD
Lapatinib—Anaphylactic shock—Epirubicin—breast cancer	2.66e-05	0.00022	CcSEcCtD
Lapatinib—Infection—Epirubicin—breast cancer	2.64e-05	0.000218	CcSEcCtD
Lapatinib—Cough—Doxorubicin—breast cancer	2.63e-05	0.000217	CcSEcCtD
Lapatinib—Diarrhoea—Capecitabine—breast cancer	2.61e-05	0.000216	CcSEcCtD
Lapatinib—Nervous system disorder—Epirubicin—breast cancer	2.61e-05	0.000215	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Methotrexate—breast cancer	2.59e-05	0.000214	CcSEcCtD
Lapatinib—Skin disorder—Epirubicin—breast cancer	2.58e-05	0.000213	CcSEcCtD
Lapatinib—Insomnia—Methotrexate—breast cancer	2.57e-05	0.000212	CcSEcCtD
Lapatinib—Myalgia—Doxorubicin—breast cancer	2.57e-05	0.000212	CcSEcCtD
Lapatinib—Arthralgia—Doxorubicin—breast cancer	2.57e-05	0.000212	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	2.55e-05	0.000211	CcSEcCtD
Lapatinib—Anorexia—Epirubicin—breast cancer	2.53e-05	0.000209	CcSEcCtD
Lapatinib—Dyspnoea—Methotrexate—breast cancer	2.53e-05	0.000209	CcSEcCtD
Lapatinib—Vomiting—Docetaxel—breast cancer	2.51e-05	0.000207	CcSEcCtD
Lapatinib—Dyspepsia—Methotrexate—breast cancer	2.5e-05	0.000207	CcSEcCtD
Lapatinib—Rash—Docetaxel—breast cancer	2.49e-05	0.000205	CcSEcCtD
Lapatinib—Dermatitis—Docetaxel—breast cancer	2.48e-05	0.000205	CcSEcCtD
Lapatinib—Decreased appetite—Methotrexate—breast cancer	2.47e-05	0.000204	CcSEcCtD
Lapatinib—Headache—Docetaxel—breast cancer	2.47e-05	0.000204	CcSEcCtD
Lapatinib—Anaphylactic shock—Doxorubicin—breast cancer	2.46e-05	0.000203	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Methotrexate—breast cancer	2.45e-05	0.000203	CcSEcCtD
Lapatinib—Fatigue—Methotrexate—breast cancer	2.45e-05	0.000202	CcSEcCtD
Lapatinib—Infection—Doxorubicin—breast cancer	2.44e-05	0.000202	CcSEcCtD
Lapatinib—Vomiting—Capecitabine—breast cancer	2.43e-05	0.000201	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Epirubicin—breast cancer	2.42e-05	0.0002	CcSEcCtD
Lapatinib—Nervous system disorder—Doxorubicin—breast cancer	2.41e-05	0.000199	CcSEcCtD
Lapatinib—Rash—Capecitabine—breast cancer	2.41e-05	0.000199	CcSEcCtD
Lapatinib—Insomnia—Epirubicin—breast cancer	2.4e-05	0.000199	CcSEcCtD
Lapatinib—Dermatitis—Capecitabine—breast cancer	2.4e-05	0.000199	CcSEcCtD
Lapatinib—Headache—Capecitabine—breast cancer	2.39e-05	0.000198	CcSEcCtD
Lapatinib—Skin disorder—Doxorubicin—breast cancer	2.39e-05	0.000197	CcSEcCtD
Lapatinib—Dyspnoea—Epirubicin—breast cancer	2.37e-05	0.000196	CcSEcCtD
Lapatinib—Anorexia—Doxorubicin—breast cancer	2.35e-05	0.000194	CcSEcCtD
Lapatinib—Nausea—Docetaxel—breast cancer	2.34e-05	0.000194	CcSEcCtD
Lapatinib—Dyspepsia—Epirubicin—breast cancer	2.34e-05	0.000193	CcSEcCtD
Lapatinib—Gastrointestinal pain—Methotrexate—breast cancer	2.32e-05	0.000192	CcSEcCtD
Lapatinib—Decreased appetite—Epirubicin—breast cancer	2.31e-05	0.000191	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Epirubicin—breast cancer	2.3e-05	0.00019	CcSEcCtD
Lapatinib—Fatigue—Epirubicin—breast cancer	2.29e-05	0.000189	CcSEcCtD
Lapatinib—Constipation—Epirubicin—breast cancer	2.27e-05	0.000188	CcSEcCtD
Lapatinib—Nausea—Capecitabine—breast cancer	2.27e-05	0.000187	CcSEcCtD
Lapatinib—Abdominal pain—Methotrexate—breast cancer	2.25e-05	0.000186	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.24e-05	0.000185	CcSEcCtD
Lapatinib—Insomnia—Doxorubicin—breast cancer	2.23e-05	0.000184	CcSEcCtD
Lapatinib—Dyspnoea—Doxorubicin—breast cancer	2.19e-05	0.000181	CcSEcCtD
Lapatinib—Gastrointestinal pain—Epirubicin—breast cancer	2.17e-05	0.00018	CcSEcCtD
Lapatinib—Dyspepsia—Doxorubicin—breast cancer	2.17e-05	0.000179	CcSEcCtD
Lapatinib—Decreased appetite—Doxorubicin—breast cancer	2.14e-05	0.000177	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Doxorubicin—breast cancer	2.12e-05	0.000176	CcSEcCtD
Lapatinib—Fatigue—Doxorubicin—breast cancer	2.12e-05	0.000175	CcSEcCtD
Lapatinib—Constipation—Doxorubicin—breast cancer	2.1e-05	0.000174	CcSEcCtD
Lapatinib—Abdominal pain—Epirubicin—breast cancer	2.1e-05	0.000174	CcSEcCtD
Lapatinib—Hypersensitivity—Methotrexate—breast cancer	2.09e-05	0.000173	CcSEcCtD
Lapatinib—Asthenia—Methotrexate—breast cancer	2.04e-05	0.000168	CcSEcCtD
Lapatinib—Gastrointestinal pain—Doxorubicin—breast cancer	2.01e-05	0.000166	CcSEcCtD
Lapatinib—Pruritus—Methotrexate—breast cancer	2.01e-05	0.000166	CcSEcCtD
Lapatinib—Hypersensitivity—Epirubicin—breast cancer	1.96e-05	0.000162	CcSEcCtD
Lapatinib—Abdominal pain—Doxorubicin—breast cancer	1.94e-05	0.000161	CcSEcCtD
Lapatinib—Diarrhoea—Methotrexate—breast cancer	1.94e-05	0.000161	CcSEcCtD
Lapatinib—Asthenia—Epirubicin—breast cancer	1.91e-05	0.000158	CcSEcCtD
Lapatinib—Pruritus—Epirubicin—breast cancer	1.88e-05	0.000155	CcSEcCtD
Lapatinib—Diarrhoea—Epirubicin—breast cancer	1.82e-05	0.00015	CcSEcCtD
Lapatinib—Hypersensitivity—Doxorubicin—breast cancer	1.81e-05	0.00015	CcSEcCtD
Lapatinib—Vomiting—Methotrexate—breast cancer	1.81e-05	0.000149	CcSEcCtD
Lapatinib—Rash—Methotrexate—breast cancer	1.79e-05	0.000148	CcSEcCtD
Lapatinib—Dermatitis—Methotrexate—breast cancer	1.79e-05	0.000148	CcSEcCtD
Lapatinib—Headache—Methotrexate—breast cancer	1.78e-05	0.000147	CcSEcCtD
Lapatinib—Asthenia—Doxorubicin—breast cancer	1.77e-05	0.000146	CcSEcCtD
Lapatinib—Pruritus—Doxorubicin—breast cancer	1.74e-05	0.000144	CcSEcCtD
Lapatinib—Vomiting—Epirubicin—breast cancer	1.69e-05	0.00014	CcSEcCtD
Lapatinib—Nausea—Methotrexate—breast cancer	1.69e-05	0.000139	CcSEcCtD
Lapatinib—Diarrhoea—Doxorubicin—breast cancer	1.68e-05	0.000139	CcSEcCtD
Lapatinib—Rash—Epirubicin—breast cancer	1.68e-05	0.000139	CcSEcCtD
Lapatinib—Dermatitis—Epirubicin—breast cancer	1.68e-05	0.000138	CcSEcCtD
Lapatinib—Headache—Epirubicin—breast cancer	1.67e-05	0.000138	CcSEcCtD
Lapatinib—Nausea—Epirubicin—breast cancer	1.58e-05	0.000131	CcSEcCtD
Lapatinib—Vomiting—Doxorubicin—breast cancer	1.56e-05	0.000129	CcSEcCtD
Lapatinib—Rash—Doxorubicin—breast cancer	1.55e-05	0.000128	CcSEcCtD
Lapatinib—Dermatitis—Doxorubicin—breast cancer	1.55e-05	0.000128	CcSEcCtD
Lapatinib—Headache—Doxorubicin—breast cancer	1.54e-05	0.000127	CcSEcCtD
Lapatinib—Nausea—Doxorubicin—breast cancer	1.46e-05	0.000121	CcSEcCtD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.18e-06	9.62e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GPX2—breast cancer	1.18e-06	9.61e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTA2—breast cancer	1.18e-06	9.61e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SLC2A1—breast cancer	1.18e-06	9.59e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NQO1—breast cancer	1.18e-06	9.59e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP3A4—breast cancer	1.18e-06	9.58e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—JUN—breast cancer	1.18e-06	9.57e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ESR1—breast cancer	1.18e-06	9.56e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.17e-06	9.53e-06	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KRAS—breast cancer	1.17e-06	9.51e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CTNNB1—breast cancer	1.17e-06	9.5e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GPX4—breast cancer	1.17e-06	9.49e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SULT1A1—breast cancer	1.17e-06	9.49e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FN1—breast cancer	1.16e-06	9.45e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP1B1—breast cancer	1.16e-06	9.42e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KRAS—breast cancer	1.15e-06	9.37e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP3A4—breast cancer	1.15e-06	9.35e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NFKBIA—breast cancer	1.15e-06	9.33e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GPX1—breast cancer	1.15e-06	9.33e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.15e-06	9.31e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—CDKN1B—breast cancer	1.14e-06	9.28e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CDKN1A—breast cancer	1.14e-06	9.28e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTA1—breast cancer	1.14e-06	9.27e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—IDH1—breast cancer	1.14e-06	9.27e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PTEN—breast cancer	1.14e-06	9.26e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOTCH1—breast cancer	1.14e-06	9.24e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HSP90AA1—breast cancer	1.14e-06	9.24e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP1A1—breast cancer	1.14e-06	9.23e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—COMT—breast cancer	1.14e-06	9.22e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP1B1—breast cancer	1.13e-06	9.19e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GSTP1—breast cancer	1.13e-06	9.18e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NAT2—breast cancer	1.13e-06	9.17e-06	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—AKT1—breast cancer	1.13e-06	9.16e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ERCC2—breast cancer	1.13e-06	9.16e-06	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	1.13e-06	9.14e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MAPK8—breast cancer	1.11e-06	9.06e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HMOX1—breast cancer	1.11e-06	9.05e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—APC—breast cancer	1.11e-06	9.04e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CG—breast cancer	1.11e-06	9.04e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KIT—breast cancer	1.11e-06	9.04e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ITPR1—breast cancer	1.11e-06	9.03e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HSP90AA1—breast cancer	1.11e-06	9.02e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NCOA1—breast cancer	1.11e-06	8.98e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—EGF—breast cancer	1.1e-06	8.94e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP19A1—breast cancer	1.09e-06	8.86e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—STK11—breast cancer	1.09e-06	8.86e-06	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—AKT1—breast cancer	1.08e-06	8.8e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—CTNNB1—breast cancer	1.08e-06	8.77e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NCOA1—breast cancer	1.08e-06	8.77e-06	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PIK3CA—breast cancer	1.08e-06	8.73e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ABCB1—breast cancer	1.07e-06	8.69e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—MAPK3—breast cancer	1.07e-06	8.66e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—STK11—breast cancer	1.06e-06	8.64e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP19A1—breast cancer	1.06e-06	8.64e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—MTHFR—breast cancer	1.06e-06	8.61e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PIK3CA—breast cancer	1.06e-06	8.6e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—SRC—breast cancer	1.06e-06	8.59e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—CDKN1A—breast cancer	1.05e-06	8.57e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTEN—breast cancer	1.05e-06	8.55e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—TYMS—breast cancer	1.05e-06	8.53e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—BRAF—breast cancer	1.05e-06	8.5e-06	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—breast cancer	1.04e-06	8.45e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GSTM1—breast cancer	1.04e-06	8.44e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NCOR1—breast cancer	1.04e-06	8.44e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PLA2G4A—breast cancer	1.04e-06	8.44e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—breast cancer	1.02e-06	8.32e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.02e-06	8.31e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—STAT3—breast cancer	1.02e-06	8.28e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IGF1—breast cancer	1.02e-06	8.28e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKT2—breast cancer	1.02e-06	8.27e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—COMT—breast cancer	1.01e-06	8.23e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GSTP1—breast cancer	1.01e-06	8.19e-06	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—HRAS—breast cancer	9.95e-07	8.08e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HMOX1—breast cancer	9.95e-07	8.08e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GPX1—breast cancer	9.94e-07	8.08e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ITPR1—breast cancer	9.93e-07	8.06e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—DPYD—breast cancer	9.9e-07	8.04e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—MED12—breast cancer	9.9e-07	8.04e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—COMT—breast cancer	9.89e-07	8.04e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GSTP1—breast cancer	9.85e-07	8e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP1A1—breast cancer	9.84e-07	8e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—HRAS—breast cancer	9.8e-07	7.96e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CD—breast cancer	9.78e-07	7.95e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CAV1—breast cancer	9.77e-07	7.94e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ERCC2—breast cancer	9.76e-07	7.93e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—SRC—breast cancer	9.76e-07	7.93e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALDOA—breast cancer	9.74e-07	7.91e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MAPK3—breast cancer	9.74e-07	7.91e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HMOX1—breast cancer	9.71e-07	7.89e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ITPR1—breast cancer	9.69e-07	7.87e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SERPINE1—breast cancer	9.68e-07	7.86e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—KRAS—breast cancer	9.58e-07	7.78e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ABCB1—breast cancer	9.55e-07	7.76e-06	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL6—breast cancer	9.52e-07	7.73e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NCOA3—breast cancer	9.46e-07	7.68e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—STAT3—breast cancer	9.41e-07	7.64e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC2A2—breast cancer	9.39e-07	7.63e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL6—breast cancer	9.38e-07	7.62e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TYMS—breast cancer	9.38e-07	7.62e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NCOR1—breast cancer	9.27e-07	7.53e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PLA2G4A—breast cancer	9.27e-07	7.53e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GSTM1—breast cancer	9.27e-07	7.53e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOS3—breast cancer	9.24e-07	7.5e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CPT1A—breast cancer	9.2e-07	7.47e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ABCG2—breast cancer	9.2e-07	7.47e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—MTR—breast cancer	9.2e-07	7.47e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—MTHFR—breast cancer	9.18e-07	7.46e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TYMS—breast cancer	9.15e-07	7.43e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PLA2G4A—breast cancer	9.05e-07	7.35e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NCOR1—breast cancer	9.05e-07	7.35e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GSTM1—breast cancer	9.05e-07	7.35e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HPGDS—breast cancer	9.02e-07	7.33e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—MAPK3—breast cancer	8.99e-07	7.3e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HBA1—breast cancer	8.97e-07	7.28e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CG—breast cancer	8.9e-07	7.23e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GPX1—breast cancer	8.88e-07	7.21e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PIK3CA—breast cancer	8.8e-07	7.15e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP1A1—breast cancer	8.79e-07	7.14e-06	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—AKT1—breast cancer	8.78e-07	7.14e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MDM2—breast cancer	8.76e-07	7.12e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KRAS—breast cancer	8.75e-07	7.11e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ACHE—breast cancer	8.75e-07	7.11e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTT1—breast cancer	8.75e-07	7.11e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—MYC—breast cancer	8.74e-07	7.1e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—RAF1—breast cancer	8.73e-07	7.09e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—TGFB1—breast cancer	8.72e-07	7.09e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ERCC2—breast cancer	8.71e-07	7.08e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—RELA—breast cancer	8.7e-07	7.06e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GPX1—breast cancer	8.66e-07	7.04e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—AKT1—breast cancer	8.65e-07	7.03e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ERBB2—breast cancer	8.64e-07	7.02e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP1A1—breast cancer	8.58e-07	6.97e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CB—breast cancer	8.53e-07	6.93e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MTOR—breast cancer	8.53e-07	6.93e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ERCC2—breast cancer	8.51e-07	6.91e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CAV1—breast cancer	8.47e-07	6.88e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP17A1—breast cancer	8.28e-07	6.73e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS1—breast cancer	8.2e-07	6.66e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ENO1—breast cancer	8.2e-07	6.66e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL8—breast cancer	8.19e-07	6.66e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—MTHFR—breast cancer	8.19e-07	6.65e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—HRAS—breast cancer	8.14e-07	6.61e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	8.09e-07	6.57e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—KRAS—breast cancer	8.08e-07	6.56e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP2D6—breast cancer	8.04e-07	6.53e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CA—breast cancer	8.04e-07	6.53e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CDKN1B—breast cancer	8e-07	6.5e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—MTHFR—breast cancer	8e-07	6.49e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NCOA2—breast cancer	7.89e-07	6.41e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CASP3—breast cancer	7.84e-07	6.37e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL2—breast cancer	7.83e-07	6.36e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CD—breast cancer	7.83e-07	6.36e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL6—breast cancer	7.79e-07	6.33e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ALB—breast cancer	7.73e-07	6.28e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CG—breast cancer	7.71e-07	6.26e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—FASN—breast cancer	7.66e-07	6.22e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCND1—breast cancer	7.63e-07	6.2e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—BCHE—breast cancer	7.62e-07	6.19e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—JUN—breast cancer	7.62e-07	6.19e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CTNNB1—breast cancer	7.56e-07	6.14e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CAV1—breast cancer	7.56e-07	6.14e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC5A5—breast cancer	7.53e-07	6.12e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HRAS—breast cancer	7.44e-07	6.04e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CA—breast cancer	7.42e-07	6.03e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MMP9—breast cancer	7.41e-07	6.02e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NOS3—breast cancer	7.39e-07	6e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CDKN1A—breast cancer	7.39e-07	6e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CAV1—breast cancer	7.38e-07	5.99e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTEN—breast cancer	7.37e-07	5.99e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NQO1—breast cancer	7.27e-07	5.91e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC2A1—breast cancer	7.27e-07	5.91e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	7.22e-07	5.86e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAPK8—breast cancer	7.21e-07	5.86e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—AKT1—breast cancer	7.19e-07	5.84e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL6—breast cancer	7.12e-07	5.78e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP1B1—breast cancer	6.97e-07	5.66e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CG—breast cancer	6.88e-07	5.59e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—HRAS—breast cancer	6.87e-07	5.58e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	6.84e-07	5.55e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SRC—breast cancer	6.83e-07	5.55e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CB—breast cancer	6.82e-07	5.54e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CD—breast cancer	6.78e-07	5.51e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS2—breast cancer	6.76e-07	5.49e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CG—breast cancer	6.72e-07	5.46e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ALB—breast cancer	6.69e-07	5.44e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—VEGFA—breast cancer	6.66e-07	5.41e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NCOA1—breast cancer	6.65e-07	5.4e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—STAT3—breast cancer	6.59e-07	5.35e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6—breast cancer	6.57e-07	5.34e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—AKT1—breast cancer	6.57e-07	5.34e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—STK11—breast cancer	6.56e-07	5.33e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP19A1—breast cancer	6.56e-07	5.33e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NOS3—breast cancer	6.4e-07	5.2e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAPK3—breast cancer	6.3e-07	5.11e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MYC—breast cancer	6.12e-07	4.97e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TGFB1—breast cancer	6.11e-07	4.96e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—COMT—breast cancer	6.09e-07	4.95e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTP1—breast cancer	6.07e-07	4.93e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—AKT1—breast cancer	6.06e-07	4.93e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CD—breast cancer	6.05e-07	4.91e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HMOX1—breast cancer	5.98e-07	4.86e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ALB—breast cancer	5.97e-07	4.85e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ITPR1—breast cancer	5.97e-07	4.85e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CB—breast cancer	5.91e-07	4.8e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CD—breast cancer	5.91e-07	4.8e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTEN—breast cancer	5.89e-07	4.79e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS2—breast cancer	5.85e-07	4.76e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ALB—breast cancer	5.83e-07	4.74e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ABCB1—breast cancer	5.74e-07	4.66e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NOS3—breast cancer	5.71e-07	4.64e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KRAS—breast cancer	5.66e-07	4.6e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TYMS—breast cancer	5.64e-07	4.58e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NOS3—breast cancer	5.58e-07	4.53e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NCOR1—breast cancer	5.57e-07	4.53e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	5.57e-07	4.53e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTM1—breast cancer	5.57e-07	4.53e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GPX1—breast cancer	5.34e-07	4.34e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP1A1—breast cancer	5.28e-07	4.29e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CB—breast cancer	5.27e-07	4.28e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ERCC2—breast cancer	5.24e-07	4.26e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS2—breast cancer	5.23e-07	4.24e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CA—breast cancer	5.2e-07	4.22e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CB—breast cancer	5.15e-07	4.18e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTEN—breast cancer	5.11e-07	4.15e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS2—breast cancer	5.1e-07	4.14e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—breast cancer	5.03e-07	4.09e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—MTHFR—breast cancer	4.93e-07	4e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HRAS—breast cancer	4.81e-07	3.91e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6—breast cancer	4.6e-07	3.74e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTEN—breast cancer	4.56e-07	3.7e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CAV1—breast cancer	4.54e-07	3.69e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTEN—breast cancer	4.45e-07	3.61e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKT1—breast cancer	4.25e-07	3.45e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CA—breast cancer	4.16e-07	3.38e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CG—breast cancer	4.14e-07	3.36e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CD—breast cancer	3.64e-07	2.96e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CA—breast cancer	3.6e-07	2.93e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALB—breast cancer	3.59e-07	2.92e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NOS3—breast cancer	3.44e-07	2.79e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AKT1—breast cancer	3.4e-07	2.76e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CA—breast cancer	3.21e-07	2.61e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CB—breast cancer	3.17e-07	2.58e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS2—breast cancer	3.14e-07	2.55e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CA—breast cancer	3.14e-07	2.55e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AKT1—breast cancer	2.94e-07	2.39e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTEN—breast cancer	2.74e-07	2.23e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AKT1—breast cancer	2.63e-07	2.13e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AKT1—breast cancer	2.56e-07	2.08e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CA—breast cancer	1.93e-07	1.57e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKT1—breast cancer	1.58e-07	1.28e-06	CbGpPWpGaD
